Patents by Inventor Jeong Chan Ra

Jeong Chan Ra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932874
    Abstract: The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 19, 2024
    Assignees: R BIO CO., LTD., NATURECELL CO., LTD.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Eun-Young Kim
  • Patent number: 11788061
    Abstract: Disclosed are a medium composition for culturing mesenchymal stem cells for the treatment of cancer which can inhibit proliferation of cancer cells, while maintaining differentiation capability and activity thereof, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition. More particularly, disclosed are a medium composition containing vitamin C and aspirin for producing mesenchymal stem cells having improved inhibitory activity against proliferation of cancer cells, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 17, 2023
    Inventor: Jeong Chan Ra
  • Publication number: 20230016479
    Abstract: The present invention relates to a method for preparing oncolytic virus-containing mesenchymal stem cells having improved cell viability, a method for storing the oncolytic virus-containing stem cells produced by the method, and a cell therapeutic agent for cancer treatment containing the oncolytic virus-containing stem cells produced by the method. More particularly, an oncolytic virus is introduced into mesenchymal stem cells, followed by treatment with aspirin, so that the infection efficiency of the oncolytic virus may be increased, the replication time of the virus may be prolonged, and lysis of the stem cells by the virus may be prevented, thereby improving the viability and survival period of the stem cells and preparing anticancer stem cells having excellent activity. The anticancer stem cell therapeutic agent produced in this way is maintained at high viability during cold storage due to aspirin treatment, and thus is very useful medically and industrially.
    Type: Application
    Filed: December 14, 2020
    Publication date: January 19, 2023
    Inventors: Jeong Chan RA, Eun-Young KIM
  • Publication number: 20220348873
    Abstract: The present invention relates to a culture method for increasing the content of NK cells. According to the present invention, the growth rate of immune cells including NK cells can be increased not only in cancer patients but also in persons who are genetically susceptible to cancer or elderly people, and an NK cell fraction and cell-killing ability can also be enhanced.
    Type: Application
    Filed: June 12, 2020
    Publication date: November 3, 2022
    Inventors: Jeong Chan RA, Sang Kyu WOO, Sung Ik CHOI
  • Publication number: 20210040453
    Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Applicants: K-STEMCELL CO., LTD
    Inventors: Jeong Chan RA, Sung Keun KANG, Il Seob SHIN
  • Patent number: 10815459
    Abstract: The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 ?m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: October 27, 2020
    Assignees: K-STEMCELL CO., LTD.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Il Seob Shin
  • Publication number: 20200010805
    Abstract: Disclosed are a medium composition for culturing mesenchymal stem cells for the treatment of cancer which can inhibit proliferation of cancer cells, while maintaining differentiation capability and activity thereof, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition. More particularly, disclosed are a medium composition containing vitamin C and aspirin for producing mesenchymal stem cells having improved inhibitory activity against proliferation of cancer cells, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition.
    Type: Application
    Filed: July 28, 2017
    Publication date: January 9, 2020
    Inventor: Jeong Chan RA
  • Publication number: 20190359942
    Abstract: The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 28, 2019
    Inventors: Jeong Chan RA, Sung Keun KANG, Eun-Young KIM
  • Patent number: 10287551
    Abstract: The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, ?-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone. According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: May 14, 2019
    Assignee: R BIO CO., LTD.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Sung-Min Kim, Mi Sook Lee, Jin Hwa Lee, Soon Ae Kwon
  • Patent number: 10172347
    Abstract: The present invention relates to a composition capable of improving storage stability of stem cells. More specifically, the present invention relates to a composition which contains a serum or a plasma for improving cold storage stability of stem cells. The composition for improving storage stability of stem cells according to the present invention can maintain a survival rate of over 90% for at least 9 days without changes in the properties, the number or the size of the stem cells, and thus is useful in the long-term transport of stem cells for cell therapy and the preparation of cell therapeutics injection products having an excellent effect.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: January 8, 2019
    Inventor: Jeong Chan Ra
  • Patent number: 9982234
    Abstract: The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 29, 2018
    Assignees: R BIO CO., LTD
    Inventors: Jeong-Chan Ra, Sung Keun Kang, Jung Youn Jo
  • Patent number: 9955898
    Abstract: A method for diagnosing cancer, comprises detecting volatile organic compounds (VOCs) contained specifically in exhaled breath of cancer patients, and more particularly, to a method for providing information for cancer diagnosis, which comprises a step of measuring whether ionized fragments of cancer-specific VOCs, which have molecular weights of (i) 69, (ii) 131 and (iii) 181, are present in exhaled breath gas collected from patients suspected of having cancer. Cancer can be early diagnosed with high sensitivity in a non-invasive manner by use of exhaled breath sampled from cancer patients. Thus, the cancer diagnosis method can diagnose cancer in a more cost-effective and rapid manner compared to conventional cancer diagnosis methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: May 1, 2018
    Assignees: R Bio Co., Ltd.
    Inventors: Jeong-Chan Ra, Soo Hyun Kim
  • Publication number: 20170313986
    Abstract: The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, ?-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone. According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 2, 2017
    Inventors: Jeong Chan RA, Sung Keun KANG, Sung-Min KIM, Mi Sook LEE, Jin Hwa LEE, Soon Ae KWON
  • Patent number: 9757506
    Abstract: An integrated kit for separating blood and concentrating PRP includes: (a) a main body that includes an upper storage portion, a lower storage portion, and a passage portion for connecting the upper storage portion and the lower storage portion; (b) a upper cover coupled to an upper end of the upper storage portion; (c) an inner stopper inserted into a lower end of the lower storage portion so as to seal the lower storage portion; (d) a closing adjustment screw which can move vertically while penetrating a hole formed at the inner stopper and seals the passage portion; and (e) a lower cover coupled to an outside of the lower end of the lower storage portion and the outside of the inner stopper to prevent the separation of the closing adjustment screw coupled to the inner stopper in case of centrifugation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 12, 2017
    Assignee: Rmedica Co., Ltd.
    Inventors: Jeong Chan Ra, Jae Wook Huh
  • Patent number: 9708584
    Abstract: The present invention relates to a medium composition for transforming stem cells from an aged person into young stem cells, and more particularly to a medium composition for culturing stem cells, which is used to rejuvenate stem cells from an aged person so as to have characteristics similar to those of the stem cells of young people, and to a method for rejuvenating stem cells, which comprises culturing stem cells from an aged person in the medium composition. According to the present invention, even mesenchymal stem cells collected from over 60 years old patients can be transformed into young mesenchymal stem cells having high differentiation ability, high telomerase activity, and high ability to express stem cell markers. Thus, the present invention can significantly increase the efficacy of cell therapy employing mesenchymal stem cells.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: July 18, 2017
    Assignee: R BIO CO., LTD.
    Inventors: Sung Keun Kang, Jeong Chan Ra, Hyeong Geun Park, Hang Young Lee
  • Publication number: 20170105406
    Abstract: The present invention relates to a composition capable of improving storage stability of stem cells. More specifically, the present invention relates to a composition which contains a serum or a plasma for improving cold storage stability of stem cells. The composition for improving storage stability of stem cells according to the present invention can maintain a survival rate of over 90% for at least 9 days without changes in the properties, the number or the size of the stem cells, and thus is useful in the long-term transport of stem cells for cell therapy and the preparation of cell therapeutics injection products having an excellent effect.
    Type: Application
    Filed: January 21, 2015
    Publication date: April 20, 2017
    Inventor: Jeong Chan RA
  • Patent number: 9433645
    Abstract: There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. According to the present invention, disruption and aggregation of cells may be prevented during transport or storage, such that the administered stem cells may stably reach the target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effect of cell therapy using stem cells.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: September 6, 2016
    Assignees: R BIO CO., LTD.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Il Seob Shin
  • Publication number: 20160090573
    Abstract: The present invention relates to a medium composition for enhancing the self-renewal ability of stem cells, which contains apelin, and a method of culturing stem cells using the medium composition. According to the present invention, stem cells can be effectively cultured to proliferate without changing the characteristics of the cells, and the telomerase activity of stem cells can be increased. Thus, the efficacy of cell therapy based on stem cells can be significantly improved.
    Type: Application
    Filed: February 6, 2014
    Publication date: March 31, 2016
    Inventors: Jeong-Chan Ra, Sung Keun Kang, Jung Youn Jo
  • Publication number: 20160081917
    Abstract: The present invention relates to a stem cell composition for intravenous administration, which contains stem cells at a concentration of 1×107 to 5×108 cells/ml, in which the stem cells have a diameter of 10-20 ?m and are present as single cells. The stem cell composition according to the present invention is suitable for intravenous administration, and enables the stem cells to securely reach a target tissue after intravascular administration so as to exhibit their activity in the target tissue. Thus, it can significantly increase the therapeutic effects of the stem cells.
    Type: Application
    Filed: February 6, 2014
    Publication date: March 24, 2016
    Inventors: Jeong-Chan Ra, Sung Keun Kang, Jung Youn Jo
  • Patent number: 9211306
    Abstract: The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: December 15, 2015
    Assignee: RNL BIO CO., LTD.
    Inventors: Jeong Chan Ra, Hang Young Lee, Jung Youn Jo, Yun Jung Kim